Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin beta chain (parasitic) is a major component of the cytoskeleton in protozoan parasites such as *Plasmodium falciparum* and *Toxoplasma gondii*.[4][7] Together with alpha-tubulin, it forms microtubules that are essential for parasite cell division, shape, intracellular motility, and host cell invasion.[4][5][6] Parasitic β-tubulin exhibits unique sequence features and is often functionally distinct from human β-tubulin, enabling development of selective inhibitors that target parasite proliferation.[2][5] Tubulin-targeting drugs interfere with microtubule assembly or dynamics, thereby blocking parasite replication or motility, making β-tubulin a validated therapeutic target for anti-parasitic intervention.[2][5]
Microtubule destabilization (by agents like parabulin binding to the colchicine site and preventing polymerization)[2]; Inhibition of parasite replication and motility by disrupting tubulin function[2][5]
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin beta chain (parasitic) (β-tubulin).